CA2933867A1 - Micromolded or 3-d printed pulsatile release vaccine formulations - Google Patents

Micromolded or 3-d printed pulsatile release vaccine formulations Download PDF

Info

Publication number
CA2933867A1
CA2933867A1 CA2933867A CA2933867A CA2933867A1 CA 2933867 A1 CA2933867 A1 CA 2933867A1 CA 2933867 A CA2933867 A CA 2933867A CA 2933867 A CA2933867 A CA 2933867A CA 2933867 A1 CA2933867 A1 CA 2933867A1
Authority
CA
Canada
Prior art keywords
formulation
antigen
release
bsa
ipv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2933867A
Other languages
English (en)
French (fr)
Inventor
Ana Jaklenec
William Gates
Philip Andrew Welkhoff
Boris Nikolic
Lowell L. Wood
Robert S. Langer
Thanh Duc Nguyen
Stephany Yi Tzeng
James J. Norman
Kevin Mchugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Tokitae LLC
Original Assignee
Massachusetts Institute of Technology
Tokitae LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Tokitae LLC filed Critical Massachusetts Institute of Technology
Publication of CA2933867A1 publication Critical patent/CA2933867A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
  • Micromachines (AREA)
CA2933867A 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations Pending CA2933867A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361916555P 2013-12-16 2013-12-16
US61/916,555 2013-12-16
PCT/US2014/070664 WO2015095230A1 (en) 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations

Publications (1)

Publication Number Publication Date
CA2933867A1 true CA2933867A1 (en) 2015-06-25

Family

ID=52396804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2933867A Pending CA2933867A1 (en) 2013-12-16 2014-12-16 Micromolded or 3-d printed pulsatile release vaccine formulations

Country Status (6)

Country Link
US (5) US10300136B2 (enExample)
EP (2) EP3763383A1 (enExample)
JP (4) JP2017507165A (enExample)
AU (1) AU2014364930B2 (enExample)
CA (1) CA2933867A1 (enExample)
WO (1) WO2015095230A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507165A (ja) 2013-12-16 2017-03-16 マサチューセッツ インスティテュート オブ テクノロジー マイクロモールド成形された、または３次元印刷されたパルス放出ワクチン製剤
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
US11395802B2 (en) * 2016-09-16 2022-07-26 Auburn University Biodegradable polymeric particles encapsulating an active agent, pharmaceutical compositions and uses thereof
US10150282B2 (en) 2016-10-14 2018-12-11 Xerox Corporation System and method for additive manufacture of chemical delivery devices using halftone screening
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
WO2018165613A1 (en) 2017-03-10 2018-09-13 Prellis Biologics, Inc. Methods and systems for printing biological material
US11085018B2 (en) 2017-03-10 2021-08-10 Prellis Biologics, Inc. Three-dimensional printed organs, devices, and matrices
EP3595515A4 (en) 2017-03-14 2020-12-30 University of Connecticut BIODEGRADABLE PRESSURE SENSOR
JP2020524483A (ja) 2017-05-25 2020-08-20 プレリス バイオロジクス，インク． 三次元印刷された器官、デバイス、およびマトリックス
KR102626745B1 (ko) 2017-05-26 2024-01-17 인피니트 머티리얼 솔루션즈, 엘엘씨 수용성 중합체 조성물
US20190076631A1 (en) * 2017-09-13 2019-03-14 Massachusetts Institute Of Technology Microdevices with complex geometries
CN111698983B (zh) 2018-01-09 2022-10-18 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
CN112074227B (zh) 2018-03-05 2024-05-14 康涅狄格大学 用于经皮和脉冲药物/疫苗递送的核壳微针平台及其制造方法
CN112334151A (zh) * 2018-06-29 2021-02-05 学校法人同志社 包含恩利卡生的制剂
JP7355016B2 (ja) * 2018-07-30 2023-10-03 三菱ケミカル株式会社 熱溶融型積層造形用材料
WO2020028436A1 (en) 2018-07-31 2020-02-06 Prellis Biologics, Inc. Optically-induced auto-encapsulation
JP7257500B2 (ja) * 2018-08-20 2023-04-13 中国科学院過程工程研究所 マイクロカプセルに基づくワクチン
US11678989B2 (en) 2019-03-01 2023-06-20 University Of Connecticut Biodegradable piezoelectric nanofiber scaffold for bone or tissue regeneration
US11826495B2 (en) 2019-03-01 2023-11-28 University Of Connecticut Biodegradable piezoelectric ultrasonic transducer system
CN110420324B (zh) * 2019-08-01 2022-07-12 临沂大学 含兔葡萄球菌抗原的免疫原性组合物及其制备方法和应用
WO2021183626A1 (en) 2020-03-10 2021-09-16 University Of Connecticut Therapeutic bandage
US12371581B2 (en) 2020-03-25 2025-07-29 Infinite Material Solutions, Llc High performance water soluble polymer compositions
US20230310710A1 (en) * 2020-04-20 2023-10-05 Hoffmann-La Roche, Inc. Method of generating a dried drug formulation
IL298019A (en) 2020-05-13 2023-01-01 Massachusetts Inst Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
US12491290B2 (en) 2020-06-08 2025-12-09 University Of Connecticut Biodegradable piezoelectric composite materials
CN112370531B (zh) * 2020-11-18 2022-09-23 金宇保灵生物药品有限公司 一种犬瘟热、犬细小、犬腺病毒、犬副流感四联活疫苗耐热保护剂及其制备方法和应用
WO2022192361A2 (en) * 2021-03-09 2022-09-15 Board Of Regents Of The University Of Nebraska Microparticle compositions and methods use thereof
WO2022272247A1 (en) * 2021-06-21 2022-12-29 William Marsh Rice University High-throughput preparation of microparticles with pulsatile release
CN113521263A (zh) * 2021-08-03 2021-10-22 苏州大学 一种3d打印的肿瘤疫苗组合物及其制备方法与应用
WO2024026039A2 (en) * 2022-07-27 2024-02-01 Board Of Regents, The University Of Texas System Multi-channeled and guided inner controlling (magic) printheads
WO2024215759A2 (en) * 2023-04-11 2024-10-17 The Regents Of The University Of California Biodegradable scaffolds for enhancing vaccine efficacy

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US5490962A (en) 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
EP0724432B1 (en) 1993-10-22 2002-09-18 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
WO1999009956A1 (en) 1997-08-29 1999-03-04 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
EP1242131A4 (en) 1999-10-12 2006-05-03 Univ Ohio State REACTIVE POLYMER VALVE, DISPENSING UNITS AND METHODS THAT USE THIS VALVE
ATE323470T1 (de) 1999-12-10 2006-05-15 Massachusetts Inst Technology Mikrochip-arzneistoffverabreichungssysteme und herstellungsverfahren
US20040175410A1 (en) 2000-04-26 2004-09-09 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US6565532B1 (en) 2000-07-12 2003-05-20 The Procter & Gamble Company Microneedle apparatus used for marking skin and for dispensing semi-permanent subcutaneous makeup
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
EP1372708B1 (en) 2001-02-13 2008-06-18 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE ARMY Vaccine for transcutaneous immunization against travellers' diarrhoea
US7122143B2 (en) * 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
MXPA04002973A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosis de liberacion modificada.
US7285289B2 (en) 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
ES2316791T3 (es) * 2002-05-06 2009-04-16 Massachusetts Institute Of Technology Forma de dosificacion controlada por difusion y metodo de fabricacion inclusive impresion tridimensional.
US8545830B2 (en) 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
WO2005010240A2 (en) 2003-07-17 2005-02-03 Microchips, Inc. Low temperature methods for hermetically sealing reservoir devices
WO2005046620A2 (en) 2003-11-12 2005-05-26 The General Hospital Corporation Variable appearance tissue markings
US9040090B2 (en) 2003-12-19 2015-05-26 The University Of North Carolina At Chapel Hill Isolated and fixed micro and nano structures and methods thereof
CA2551644C (en) 2003-12-24 2014-03-04 Cerus Corporation Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of usethereof
CN1921884B (zh) 2003-12-24 2012-02-08 塞鲁斯公司 重组核酸分子,表达盒和细菌,及其使用方法
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006121819A1 (en) 2005-05-06 2006-11-16 Board Of Regents, The University Of Texas System Methods for fabricating nano and microparticles for drug delivery
KR20080024206A (ko) 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
WO2007012114A1 (en) 2005-07-25 2007-02-01 Nanotechnology Victoria Pty Ltd Microarray device
WO2007016337A2 (en) 2005-07-28 2007-02-08 Mformation Technologies, Inc. System and method for service quality management for wireless devices
US20070141106A1 (en) 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US20080026040A1 (en) * 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
US8349326B2 (en) 2007-02-20 2013-01-08 Tufts University Methods and systems for multi-antibody therapies
WO2009042231A2 (en) 2007-09-27 2009-04-02 Akina, Inc. Sol-gel phase-reversible hydrogel templates and uses thereof
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
EP2254554A1 (en) 2008-02-25 2010-12-01 Novavax, Inc. Sugar glassified virus like particles (vlps)
US10463608B2 (en) 2008-09-29 2019-11-05 The Corporation Of Mercer University Microneedle-based transdermal delivery system and method of making same
EP2427179A4 (en) 2009-05-04 2013-09-11 Psivida Inc POROUS PARTICLES FOR THE RELEASE OF SILICIUM MEDICINES
AU2010276511B2 (en) 2009-07-31 2013-09-19 Kindeva Drug Delivery L.P. Hollow microneedle arrays
US10046109B2 (en) 2009-08-12 2018-08-14 Progenity, Inc. Drug delivery device with compressible drug reservoir
WO2011156641A2 (en) 2010-06-09 2011-12-15 Kaspar Roger L Microneedle arrays for active agent delivery
MX373096B (es) * 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
WO2012088306A2 (en) 2010-12-22 2012-06-28 Psivida Us, Inc. Two-piece injectable drug delivery device with heat-cured seal
JP2012235899A (ja) 2011-05-12 2012-12-06 Bioserentack Co Ltd 大量の目的物質を皮膚内へデリバリーするためのマイクロニードル・アレイ・チップ
US20130046182A1 (en) 2011-08-16 2013-02-21 Elwha LLC, a limited liability company of the State of Delaware Devices and Methods for Recording Information on a Subject's Body
KR101542549B1 (ko) 2011-09-02 2015-08-06 산디아 코포레이션 바이오센싱 및 약물 전달을 위한 마이크로니들 어레이
CN103251941A (zh) 2012-02-16 2013-08-21 海南大学 动物病毒性疫苗脉冲释放系统、其制备方法及用途
IN2014DN10765A (enExample) 2012-05-30 2015-09-04 Univ California
TWI554289B (zh) 2012-06-29 2016-10-21 國立成功大學 鑲嵌式經皮藥物釋放貼片及其製造方法
JP2015522342A (ja) 2012-06-29 2015-08-06 イーエルシー マネージメント エルエルシー １つ以上の化粧品成分を含むマイクロニードル
RU2695536C2 (ru) 2013-03-12 2019-07-23 Айпоинт Фармасьютикалз Юэс, Инк. Устройство для доставки лекарственных средств, содержащее частицы носителя на основе кремния
ITTO20130284A1 (it) 2013-04-09 2014-10-10 Fond Istituto Italiano Di Tecnologia Procedimento per la produzione di microparticelle polimeriche sagomate
US10232157B2 (en) 2013-07-16 2019-03-19 3M Innovative Properties Company Hollow microneedle with beveled tip
JP2017507165A (ja) 2013-12-16 2017-03-16 マサチューセッツ インスティテュート オブ テクノロジー マイクロモールド成形された、または３次元印刷されたパルス放出ワクチン製剤
AU2015264090A1 (en) 2014-05-21 2016-12-15 Invention Development Management Company, Llc Tattoo and tattoo applicator for animal lifecycle monitoring
AU2015343369B2 (en) 2014-11-03 2018-11-22 Georgia Tech Research Corporation Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2016176327A1 (en) 2015-04-27 2016-11-03 University Of Rochester Nanoparticle therapeutics for treating skin inflammatory disorders
US20190336532A1 (en) 2016-12-21 2019-11-07 Fred Hutchinson Cancer Research Center Scaffolds to treat solid tumor cells and escape variants
CN111093629A (zh) 2017-07-16 2020-05-01 麻省理工学院 微针纹身贴剂和其用途
US20190076631A1 (en) 2017-09-13 2019-03-14 Massachusetts Institute Of Technology Microdevices with complex geometries
GB201919428D0 (en) 2019-12-30 2020-02-12 Immodulon Therapeutics Ltd Immunotherapeutic treatment of cancer
IL298019A (en) 2020-05-13 2023-01-01 Massachusetts Inst Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
CN113350564B (zh) 2021-05-20 2023-03-10 诺一迈尔(苏州)生命科技有限公司 生物可降解组织粘合贴片及其制备方法

Also Published As

Publication number Publication date
US20210205444A1 (en) 2021-07-08
AU2014364930B2 (en) 2017-06-15
JP2021120413A (ja) 2021-08-19
WO2015095230A1 (en) 2015-06-25
US10300136B2 (en) 2019-05-28
US10960073B2 (en) 2021-03-30
US20260224697A1 (en) 2026-08-06
US12622963B2 (en) 2026-05-12
JP2017507165A (ja) 2017-03-16
US20190328871A1 (en) 2019-10-31
US20150165020A1 (en) 2015-06-18
AU2014364930A1 (en) 2016-07-14
JP7682019B2 (ja) 2025-05-23
EP3763383A1 (en) 2021-01-13
US20240181047A1 (en) 2024-06-06
US11975069B2 (en) 2024-05-07
EP3082852B1 (en) 2020-06-17
JP2020055818A (ja) 2020-04-09
JP2023075311A (ja) 2023-05-30
EP3082852A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
US12622963B2 (en) Micromolded or 3-D printed pulsatile release vaccine formulations
CA3082793C (en) Microdevices with complex geometries
US9878036B2 (en) Immunomodulatory compositions comprising a polymer matrix and an oil phase
Mao et al. Recent advances in polymeric microspheres for parenteral drug delivery—part 2
Hajavi et al. Optimization of PLGA formulation containing protein or peptide‐based antigen: recent advances
AU2009290656A1 (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
Sinsinbar et al. Amphiphilic block copolymer nanostructures as a tunable delivery platform: perspective and framework for the future drug product development
Prashant et al. Nanoparticle based tailoring of adjuvant function: the role in vaccine development
Kaur et al. Polymer particulates in drug delivery
Diesner et al. Use of lectin-functionalized particles for oral immunotherapy
US20110163469A1 (en) High-throughput fabrication of microparticles
Takada Microfabrication derived DDS: From batch to individual production
Nechaeva Development of oral microencapsulated forms for delivering viral vaccines
Shah et al. Strategies for Formulation and Systemic Delivery of Therapeutic Proteins
Schiller Scalable processes to manufacture nanoparticulate dosage forms for oral vaccination
Pal et al. Drug Delivery to the Immune System: Immunotherapies and Vaccines
Wang et al. Microspheres and microcapsules for protein drug delivery
Lin et al. The preparation and characteristic of poly (lactide co–glycolide) microspheres as novel antigen delivery systems
Lahane et al. Role of Nanoparticle Formulation for the Combination Delivery of Multiple Antigens
as Promising Biolological Medicinal Chemistry
Jang Development of a lower intestine targeting mucoadhesive platform of oral drug delivery
Guan Fabrication of polymeric microparticles for drug delivery
Noureddine et al. Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160614

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260126

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20260525

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260525

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20260622

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260622

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260622

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260622

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260622

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260622